Edition:
India

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

88.51USD
24 Feb 2020
Change (% chg)

-- (--)
Prev Close
$88.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
298,839
52-wk High
$109.94
52-wk Low
$7.64

Summary

Name Age Since Current Position

Herriot Tabuteau

50 2018 Chairman of the Board, President, Chief Executive Officer, Founder

Nick Pizzie

44 2018 Chief Financial Officer

Mark Jacobson

35 2017 Senior Vice President - Operations, Secretary

Cedric O'Gorman

44 2017 Senior Vice President - Clinical Development and Medical Affairs

David Marek

2019 Chief Commercial Officer

Roger Jeffs

57 2016 Lead Independent Director

Mark Coleman

51 2014 Independent Director

Myrtle Potter

60 2017 Independent Director

Mark Saad

49 2014 Independent Director

Biographies

Name Description

Herriot Tabuteau

Dr. Herriot Tabuteau M.D is the Chief Executive Officer, President, Chairman of the Company. Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC (formerly Versant Capital Management LLC), one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Nick Pizzie

Mr. Nick Pizzie CPA is the Chief Financial Officer of the Company effective From May 16, 2018. He was the Vice President and Chief Financial Officer of Pierre Fabre USA, the U.S. affiliate of Pierre Fabre, prior to joining the Company. Previously, he was Senior Finance Director at Immucor. Prior to Immucor, He held positions of increasing responsibility in finance and accounting at Merck and Pfizer. Mr. Pizzie began his career at Arthur Andersen, where he served as staff auditor. He earned his BS in Accounting, BA in Economics, and MBA in Finance, and Supply Side Logistics, from Rutgers University.

Mark Jacobson

Mr. Mark Jacobson is the Senior Vice President - Operations, Secretary of Axsome Therapeutics, Inc. Mr. Jacobson has served as our Senior Vice President, Operations since September, 2017, when he was promoted from his role as our Vice President, Operations, which he had been serving as since October 2015. Prior to that, Mr. Jacobson served as our Senior Director of Operations from April 2014 until October 2015. Prior to joining Axsome, he was Director of Corporate Development at Stemline Therapeutics, Inc., where he played a critical role in advancing the company from a 3-person team in 2010 to the successful completion of an initial public offering and secondary public offering in 2013, which together raised approximately $100 million for the company. While at Stemline, Mr. Jacobson's responsibilities spanned investor relations, public relations, corporate operations, and intellectual property. Mr. Jacobson began his career in healthcare communications at Publicis Healthcare Communications Group. Mr. Jacobson earned a Master of Arts in Biotechnology from Columbia University and a Bachelor of Science in Biology from Iowa State University.

Cedric O'Gorman

Dr. Cedric O'Gorman M.D. is the Senior Vice President - Clinical Development and Medical Affairs of the Company. Prior to joining us, Dr. O'Gorman was the Vice President of Medical Affairs at Intra-Cellular Therapies since December 2014. Before that, Dr. O'Gorman was the U.S. medical lead for psychiatry at Genentech/Roche. Prior to Genentech/Roche, Dr. O'Gorman spent 5 years at Pfizer representing medical affairs on several branded neuroscience products including Geodon for schizophrenia and bipolar disorder, and Pristiq for major depressive disorder. Dr. O'Gorman received his medical degree from the National University of Ireland, in Galway, Ireland, trained at the Institute of Psychiatry, in London, England, and earned his Master of Business Administration from the New York University Stern School of Business.

David Marek

Mr. David C. Marek is appointed as the Chief Commercial Officer of the Company., effective August 31, 2019. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig™ for migraine prevention, achieving industry-record launch performance for a biologic. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen's U.S. Inflammation and Nephrology business leading it to attain over $9 billion in annual revenue. Before Amgen, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD, one of the largest providers of healthcare digital content, and the top healthcare website by unique visitors. Prior to WebMD, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising where he developed and implemented creative strategies to grow many of the most successful pharmaceutical brands. Mr. Marek began his career at Eli Lilly and Company, followed by AstraZeneca, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.

Roger Jeffs

Dr. Roger A. Jeffs Ph.D is the Lead Independent Director of Axsome Therapeutics, Inc. Dr. Jeffs has been a member of our board of directors since December 2014. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments. Dr. Jeffs retired from United Therapeutics Corporation in 2016, where he worked for 18 years. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as director of research, development, and medical and served as its president and chief operating officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the Board of Directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of 6 products for rare diseases, and managed the commercial effort that lead to a consistent >20% CAGR and $1.5B revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co. where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs currently serves on the Board of Directors of Axovant, Dova Pharmaceuticals, Albireo Pharma, and Sangamo Therapeutics. Dr. Jeffs' scientific background and business experience, coupled with his experience as a chief executive officer of a publicly-traded biotechnology company, provide him with the qualifications and skills to serve as a director.

Mark Coleman

Dr. Mark Coleman M.D is an Independent Director of Axsome Therapeutics, Inc. Dr. Coleman has been a member of our board of directors since December 2014. In addition, from 2012 to 2014, Dr. Coleman served as a consultant to us. Since 2005, Dr. Coleman has served as the Medical Director of the Baltimore branch of National Spine and Pain Centers, or NSPC, the nation's largest interventional pain management group. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University. Dr. Coleman's medical background, particularly his specialized experience in the treatment of pain, make him qualified to serve on our board.

Myrtle Potter

Ms. Myrtle Stephens Potter is an Independent Director of the Company. Ms. Potter has been a member of our board of directors since June 2017. Ms. Potter is the Chief Executive Officer and Founder of Myrtle Potter & Company, a healthcare and life science advisory firm, which she founded in 2005. Ms. Potter previously served as the President, Commercial Operations and Chief Operating Officer of Genentech, Inc. from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech, Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, she held executive operating positions at Bristol-Myers Squibb Company and Merck & Co., Inc. While at Merck, she started the joint venture entity Astra Merck Inc., which through merger, later became AstraZeneca plc. She began her career with Procter & Gamble Co. Patient Care Products. Ms. Potter currently serves on the Board of Directors of Liberty Mutual Holding Company, Rite Aid Corporation, Insmed Incorporated, and Proteus Digital Health, Inc. She is also on the Board of Trustees of The University of Chicago and previously served on the boards of Everyday Health, LLC, Medco Health Solutions, Inc., and Amazon.com, Inc. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago. Ms. Potter's years of experience in the biotechnology industry, including extensive commercial and operational experience leading pharmaceutical companies in bringing new therapies to market, provide her with the qualifications and skills to serve as a director.

Mark Saad

Mr. Mark E. Saad is Independent Director of Axsome Therapeutics, Inc. Mr. Saad has been a member of our board of directors since December 2014. Mr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2017, he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Previously, he served as Chief Financial Officer of Cytori Therapeutics from 2004 to 2014, where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the Chief Operating Officer of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a Bachelor of Arts from Villanova University. Through his years of experience as a chief financial officer, and his experience in the investment banking field, Mr. Saad provides valuable financial and leadership experience to the board.

Basic Compensation